Full Press Release Details
BridgeBio Pharma's QED Therapeutics And Helsinn Group Announce FDA Approval Of TRUSELTIQ (infigratinib) For Patients With Cholangiocarcinoma.
BBIO
BridgeBio Pharma's QED Therapeutics And Helsinn Group Announce FDA Approval Of TRUSELTIQ (infigratinib) For Patients With Cholangiocarcinoma
Key Takeaway: BridgeBio Pharma's QED Therapeutics And Helsinn Group Announce FDA Approval Of TRUSELTIQ (infigratinib) For Patients With Cholangiocarcinoma
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+41%
120-day peak, hindsight
Typical move
3.6%
average across 13 past catalysts
Cash runway
~30 mo
Minimal dilution risk
Lead asset
acoramidis
Phase 3 · Amyloidosis